In a report released today, Serge Belanger from Needham maintained a Buy rating on Amphastar Pharmaceuticals (NASDAQ: AMPH), with a price target of $22. The company’s shares opened today at $17.32.
According to TipRanks.com, Belanger is a 3-star analyst with an average return of 4.3% and a 40.8% success rate. Belanger covers the Healthcare sector, focusing on stocks such as Pacira Pharmaceuticals, Heron Therapeutics, and Aerie Pharma.
Amphastar Pharmaceuticals has an analyst consensus of Moderate Buy, with a price target consensus of $24, a 38.6% upside from current levels. In a report issued on August 8, Piper Jaffray also reiterated a Buy rating on the stock with a $24 price target.
.
See today’s analyst top recommended stocks >>
The company has a one-year high of $20.45 and a one-year low of $14.40. Currently, Amphastar Pharmaceuticals has an average volume of 233.8K.
Based on the recent corporate insider activity of 59 insiders, corporate insider sentiment is neutral on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Amphastar Pharmaceuticals, Inc. engages in the development, manufacture, market, and sale of technically challenging and proprietary injectable, inhalation, and intranasal products. It operates through Finished Pharmaceutical Products, and Active Pharmaceutical Ingredients Products segments.
